Molecular Partners (6ML0) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

6ML0 Analyst Ratings

Strong Buy

3 Buy

0 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Molecular

Partners

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

6ML0 Stock 12 Month Forecast

Average Price Target

€10.73

▲(193.16% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Molecular Partners in the last 3 months. The average price target is €10.73 with a high forecast of €11.16 and a low forecast of €10.30. The average price target represents a 193.16% change from the last price of €3.66.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","12":"€12","3.75":"€3.75","6.5":"€6.5","9.25":"€9.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11.15868338,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€11.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.72950325,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€10.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.30032312,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€10.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.75,6.5,9.25,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.3,3.904514106153846,4.509028212307692,5.113542318461539,5.718056424615384,6.32257053076923,6.927084636923077,7.5315987430769225,8.13611284923077,8.740626955384617,9.345141061538461,9.949655167692306,10.554169273846153,{"y":11.15868338,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.3,3.87150025,4.4430005,5.01450075,5.5860009999999996,6.15750125,6.7290015,7.3005017500000005,7.872002,8.44350225,9.015002500000001,9.586502750000001,10.158003,{"y":10.72950325,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.3,3.8384863938461535,4.376972787692307,4.915459181538461,5.4539455753846156,5.992431969230768,6.530918363076923,7.069404756923077,7.60789115076923,8.146377544615383,8.684863938461538,9.223350332307692,9.761836726153845,{"y":10.30032312,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.16,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.08,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.66,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.16,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.26,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.56,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.36,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.3,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€11.16

Average Price Target€10.73

Lowest Price Target€10.30

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Charles Zhu

LifeSci Capital

€10.3

Buy

181.43%

Upside

Reiterated

08/25/26

Molecular Partners: Pipeline Momentum and Early Safety Data Support Unchanged $12 Price Target and Buy Rating

Robert Burns

H.C. Wainwright

€11.16

Buy

204.88%

Upside

Reiterated

07/06/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (NASDAQ: ALNY), Molecular Partners (NASDAQ: MOLN) and Exelixis (NASDAQ: EXEL)

Jonathan Chang

Leerink Partners

―

Buy

―

Reiterated

06/02/26

Analysts Offer Insights on Healthcare Companies: Disc Medicine (NASDAQ: IRON), Molecular Partners (NASDAQ: MOLN) and Park Dental Partners, Inc. (NASDAQ: PARK)

William Maughan

Clear Street

€6.87

Buy

87.62%

Upside

Reiterated

03/13/26

Molecular Partners (MOLN) Gets a Buy from Clear Street

Richard Vosser

J.P. Morgan

€3.86→€3.43

Hold

-6.19%

Downside

Reiterated

09/03/25

Molecular Partners price target lowered to $4 from $4.50 at JPMorganMolecular Partners price target lowered to $4 from $4.50 at JPMorgan

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Charles Zhu

LifeSci Capital

€10.3

Buy

181.43%

Upside

Reiterated

08/25/26

Molecular Partners: Pipeline Momentum and Early Safety Data Support Unchanged $12 Price Target and Buy Rating

Robert Burns

H.C. Wainwright

€11.16

Buy

204.88%

Upside

Reiterated

07/06/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (NASDAQ: ALNY), Molecular Partners (NASDAQ: MOLN) and Exelixis (NASDAQ: EXEL)

Jonathan Chang

Leerink Partners

―

Buy

―

Reiterated

06/02/26

Analysts Offer Insights on Healthcare Companies: Disc Medicine (NASDAQ: IRON), Molecular Partners (NASDAQ: MOLN) and Park Dental Partners, Inc. (NASDAQ: PARK)

William Maughan

Clear Street

€6.87

Buy

87.62%

Upside

Reiterated

03/13/26

Molecular Partners (MOLN) Gets a Buy from Clear Street

Richard Vosser

J.P. Morgan

€3.86→€3.43

Hold

-6.19%

Downside

Reiterated

09/03/25

Molecular Partners price target lowered to $4 from $4.50 at JPMorganMolecular Partners price target lowered to $4 from $4.50 at JPMorgan

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ODTXOdyssey Therapeutics, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Molecular Partners

3 Months

Charles ZhuLifeSci Capital

Success Rate

8/13 ratings generated profit

Average Return

+2.70%

Copying Charles Zhu's trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +2.70% per trade.

1 Year

Charles ZhuLifeSci Capital

Success Rate

12/13 ratings generated profit

Average Return

+9.44%

Copying Charles Zhu's trades and holding each position for 1 Year would result in 92.31% of your transactions generating a profit, with an average return of +9.44% per trade.

2 Years

Charles ZhuLifeSci Capital

Success Rate

13/13 ratings generated profit

Average Return

+13.11%

Copying Charles Zhu's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +13.11% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

6ML0 Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 6ML0 has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 6ML0 average Analyst price target in the past 3 months is 10.73.

Each month's total comprises the sum of three months' worth of ratings.

6ML0 Financial Forecast

6ML0 Earnings Forecast

The previous quarter’s earnings for 6ML0 were -€0.37.

6ML0 Sales Forecast

The previous quarter’s earnings for 6ML0 were €0.00.

6ML0 Stock Forecast FAQ

What is DE:6ML0’s average 12-month price target, according to analysts?

Based on analyst ratings, Molecular Partners’s 12-month average price target is 10.73.

What is DE:6ML0’s upside potential, based on the analysts’ average price target?

Molecular Partners has 193.16% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Molecular Partners a Buy, Sell or Hold?

Molecular Partners has a consensus rating of Strong Buy, which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.

What is Molecular Partners’s share price target?

The average share price target for Molecular Partners is 10.73. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €11.16 ,and the lowest forecast is €10.30. The average share price target represents 193.16% Increase from the current price of €3.66.

What do analysts say about Molecular Partners?

Molecular Partners’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of Molecular Partners?

To buy shares of DE:6ML0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Molecular Partners (6ML0) Stock Forecast & Price Target

6ML0 Analyst Ratings

6ML0 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Molecular Partners

6ML0 Analyst Recommendation Trends

6ML0 Financial Forecast

6ML0 Earnings Forecast

6ML0 Sales Forecast

6ML0 Stock Forecast FAQ

Detailed List of Analyst Forecasts